The AHA today filed an amicus brief in the U.S. Court of Appeals for the D.C. Circuit, defending the Department of Health and Human Services’ decision to prevent drug companies from implementing a 340B rebate model. The brief was filed in a consolidated appeal involving five drug companies. The AHA said such models from drug companies would devastate hospitals financially.  

 

“In a world of finite resources, 340B hospitals will have no choice but to divert funds away from patient services and towards burdensome compliance,” the AHA wrote. “All of these consequences ‘frustrate’ the goal of the 340B statute.” 

Authored in-house by Chad Golder, AHA general counsel, the AHA was joined in the filing by the Children’s Hospital Association, the Association of American Medical Colleges and America’s Essential Hospitals.

Related News Articles

Headline
A JAMA study published Aug. 18 found that plan design changes by Medicare Part D insurers, particularly for Medicare Advantage plans, following passage of the…
Headline
Applications for the 2026 AHA Rural Hospital Excellence in Innovation Award close Aug. 29 at 1 p.m. ET. The award honors rural hospitals leading the way in…
Headline
The Health Resources and Services Administration has awarded more than $15 million in grants to 58 rural health organizations for four-year projects as part of…
Headline
The Centers for Medicare & Medicaid Services has issued the 2025-2026 Medicaid Managed Care Rate Development Guide for states to use when setting managed…
Headline
The AHA Aug. 11 urged the Centers for Medicare & Medicaid Services to prioritize payments to hospitals from the Rural Health Transformation Program. The…
Headline
The AHA, joined by several other national groups representing 340B hospitals, Aug. 8 urged the Health Resources and Services Administration to extend the…